References
- Boswell CA , BumbacaD , FielderPJ , KhawliLA. Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. AAPS J.14(3), 612–618 (2012).
- Doogue MP , PolasekTM. The ABCD of clinical pharmacokinetics. Ther. Adv. Drug Saf.4(1), 5–7 (2013).
- Kraynov E , KamathAV , WallesMet al. Current approaches for absorption, distribution, metabolism, and excretion characterization of antibody-drug conjugates: an industry white paper. Drug Metab. Dispos.44(5), 617–623 (2016).
- Tang MT , KeirME , EricksonRet al. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-beta7 integrin therapy for inflammatory bowel disease. Aliment. Pharmacol. Ther.47(11), 1440–1452 (2018).
- Leipold D , PrabhuS. Pharmacokinetic and pharmacodynamic considerations in the design of therapeutic antibodies. Clin. Transl. Sci.12(2), 130–139 (2019).
- Mankarious S , LeeM , FischerSet al. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J. Lab. Clin. Med.112(5), 634–640 (1988).
- Liu L . Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell.9(1), 15–32 (2018).
- Spiro RG . Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology12(4), 43R–56R (2002).
- Aebi M . N-linked protein glycosylation in the ER. Biochim. Biophys. Acta1833(11), 2430–2437 (2013).
- Brockhausen I . Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep.7(6), 599–604 (2006).
- Varki A . Biological roles of glycans. Glycobiology27(1), 3–49 (2017).
- Reusch D , TejadaML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology25(12), 1325–1334 (2015).
- McFarlane IG . Hepatic clearance of serum glycoproteins. Clin Sci (Lond.)64(2), 127–135 (1983).
- Schwartz AL . The hepatic asialoglycoprotein receptor. CRC Crit. Rev. Biochem.16(3), 207–233 (1984).
- Flintegaard TV , ThygesenP , Rahbek-NielsenHet al. N-glycosylation increases the circulatory half-life of human growth hormone. Endocrinology151(11), 5326–5336 (2010).
- Weiss P , AshwellG. The asialoglycoprotein receptor: properties and modulation by ligand. Prog. Clin. Biol. Res.300, 169–184 (1989).
- Chung S , NguyenV , LinYLet al. An in vitro FcRn-dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans. MAbs11(5), 942–955 (2019).
- Bas M , TerrierA , JacqueEet al. Fc sialylation prolongs serum half-life of therapeutic antibodies. J. Immunol.202(5), 1582–1594 (2019).
- Stefanich EG , RenS , DanilenkoDMet al. Evidence for an asialoglycoprotein receptor on nonparenchymal cells for O-linked glycoproteins. J. Pharmacol. Exp. Ther.327(2), 308–315 (2008).